Abstracts tagged "autoantibodies"

Abstract Number: 1112 • 2016 ACR/ARHP Annual Meeting
Hypoxia Modulates Neutrophil Integrin Expression, Adhesion and Trans-Endothelial Migration
Akif A. Khawaja^1,2, Charis Pericleous^3,4, Vera M. Ripoll¹, Joanna C. Porter⁵ and Ian Giles³, ¹Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ²Centre for Inflammation and Tissue Repair, Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom, ³Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom, ⁴Imperial College Vascular Sciences, National Heart and Lung Institute, Imperial College Vascular Sciences, National Heart and Lung Institute, London, United Kingdom, ⁵Centre for Inflammation and Tissue Repair, Division of Medicine, Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom
Background/Purpose: Dysregulation of neutrophil activation is important in the pathogenesis of various inflammatory and autoimmune rheumatic diseases (ARDs), including RA, SLE and APS. Neutrophils are…
Abstract Number: 2423 • 2016 ACR/ARHP Annual Meeting
Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity
Hanna Kim¹, Terrance P. O'Hanlon², Adriana Almeida de Jesus³, Yan Huang³, Ira N. Targoff^4,5, Frederick W. Miller², Raphaela Goldbach-Mansky⁶ and Lisa G. Rider², ¹NIAMS/NIH, Bethesda, MD, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: JDM is a complex autoimmune disease with an interferon (IFN) signature, with a reported correlation with disease activity. Clinical features vary among myositis-specific autoantibody…
Abstract Number: 467 • 2016 ACR/ARHP Annual Meeting
Interleukin-21-Signaling in B Cells, but Not in T Cells, Is Indispensable for Development of Collagen-Induced Arthritis in Mice
Koji Sakuraba^1,2, Kenjiro Fujimura^1,2, Hisaaki Miyahara¹ and Hisakata Yamada², ¹Clinical Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, ²Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
Background/Purpose: IL-21 is a T cell-derived cytokine whose receptor is expressed on variety of cells in immune system. IL-21was reported to be involved in the…
Abstract Number: 1208 • 2016 ACR/ARHP Annual Meeting
High-Throughput Screening Discovers Multiple Novel Autoantibodies in Rheumatoid Arthritis, Systemic Lupus, Systemic Sclerosis and Sjogrens Syndrome
Peter Schulz-Knappe¹, Hans-Dieter Zucht¹, Petra Budde¹, Heike Göhler¹, Daniel Wirtz¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Torsten Witte³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁴Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany
Background/Purpose: Diagnostic biomarkers are decision-making tools in clinical lab routine and are of growing importance for clinical management of patients. In autoimmune diseases, one important…
Abstract Number: 2424 • 2016 ACR/ARHP Annual Meeting
Novel Autoantigens for Anti- Endothelial Cell Antibodies in Pediatric Rheumatic Diseases Identified By Proteomics
Rie Karasawa¹, Mayumi Tamaki¹, Toshiko Sato¹, Kazuo Yudoh² and James Jarvis³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, ³Pediatrics, The University at Buffalo, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM), a systemic autoimmune vasculopathy, and juvenile idiopathic arthritis (JIA) are representative rheumatic diseases in children. However the pathogenesis of these diseases…
Abstract Number: 493 • 2016 ACR/ARHP Annual Meeting
The 2010 ACR/EULAR Criteria Are Not Sufficiently Accurate in the Early Identification of Autoantibody-Negative Rheumatoid Arthritis
Debbie M. Boeters¹, Cécile Gaujoux-Viala², Arnaud Constantin³ and Annette H.M. van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ³Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: The 2010-ACR/EULAR criteria were derived to classify RA earlier in time. Previous studies indeed observed that the 2010-criteria were fulfilled earlier than the 1987-criteria.…
Abstract Number: 1214 • 2016 ACR/ARHP Annual Meeting
Autoantibody Reactivities Correlated with SLE Disease Activity Identified By the SLE-key® iCHIP® Platform
Chaim Putterman¹, Pennina Safer², Keren Jakobi², Rachel Sorek², Ilana Gilkaite², Kyle Ferber³, Steve Wallace³, Amanda Harris Altice³, D. Scott Batty³ and Irun R Cohen^2,4, ¹Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray LTD, Rehovot, Israel, ³ImmunArray Inc., Richmond, VA, ⁴Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: We have developed an antigen microarray technology to study antibody profiles to elucidate and diagnose clinical states of SLE patients – the iCHIP® SLE-key®…
Abstract Number: 2634 • 2016 ACR/ARHP Annual Meeting
Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis
Ethan Grant¹, Martin Schwickart², Alex Godwood³, Rachel Moate³, Esther Song², Carlos Chavez², Marius Albulescu⁴, David Close⁴, Meina Liang², Tomas Mustelin⁵, Zhengbin Yao⁶ and Koustubh Ranade¹, ¹Translational Medicine, MedImmune, Gaithersburg, MD, ²Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD, ³MedImmune, Cambridge, United Kingdom, ⁴Clinical Development, MedImmune, Cambridge, United Kingdom, ⁵Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD, ⁶Respiratory, Inflammation and Autoimmunity iMED, MedImmune, Gaithersburg, MD
Background/Purpose: Mavrilimumab is an anti-GM-CSF receptor Ab that has recently demonstrated clinical efficacy in Phase 2 studies in rheumatoid arthritis (RA) patients. Predictive biomarkers to…
Abstract Number: 15L • 2015 ACR/ARHP Annual Meeting
Identification of Four-and-a-Half-LIM Domain 1 (FHL1) As a New Autoantibody Target in Idiopathic Inflammatory Myopathies
Inka Albrecht¹, Cecilia Wick¹, Åsa Hallgren², Anna Tjärnlund¹, Kanneboyina Nagaraju³, Felipe Andrade⁴, Kathryn Thompson⁵, William Coley⁵, Aditi Phadke⁶, Lina-Marcela Diaz-Gallo¹, Matteo Bottai⁷, Inger Nennesmo⁸, Karine Chemin⁹, Jessica Herrath¹⁰, Karin Johansson¹, Anders Wikberg¹, Jimmy Ytterberg¹, Roman Zubarev¹, Olof Danielsson¹¹, Olga Krystufkova¹², Jiri Vencovsky¹³, Nils Landegren², Marie Wahren-Herlenius¹⁴, Leonid Padyukov¹⁵, Olle Kämpe² and Ingrid E. Lundberg¹⁶, ¹Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Experimental Endocrinology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³The George Washington University Medical Center, Children's National Medical Center, Washington, DC, ⁴Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Children's National Medical Center, Washington, DC, ⁶Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, ⁷Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁸Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Medicine, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁰Department of Medicine,, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ¹¹Department of Clinical and Experimental Medicine, Division of Neurology, Faculty of Health Sciences, Linköping University, Linköping, Sweden, ¹²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ¹⁴Department of Medicine, Experimental Rheumatology Unit, Solna, Sweden, ¹⁵Department of medicine, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁶Karolinska University Hospital, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of rare systemic autoimmune diseases collectively called myositis causing progressive muscle weakness. Interestingly, myositis-specific autoantibodies described…
Abstract Number: 285 • 2015 ACR/ARHP Annual Meeting
Tobacco Smoking in Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies
Adam Schiffenbauer¹, Natalie Smith², Lisa G Rider¹ and Frederick W. Miller³, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Statistics, Purdue University, Allison Park, PA, ³Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD
Background/Purpose: Smoking has been found to be a risk or protective factor in certain autoimmune diseases. Yet, its role in the idiopathic inflammatory myopathies (IIM)…
Abstract Number: 1114 • 2015 ACR/ARHP Annual Meeting
Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity
Sarah Kongpachith¹, WH Robinson¹, Sara Rasmussen², Robert Clancy³ and Jill P. Buyon³, ¹Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL) is an uncommon autoimmune disease classically manifest as permanent complete heart block and/or transient cutaneous lesions. By definition of NL, there…
Abstract Number: 1885 • 2015 ACR/ARHP Annual Meeting
Identification and Clinical Correlations of Rare Autoantibodies in Systemic Sclerosis and Poly/Dermatomyositis Patients
Angela Ceribelli^1,2, Natasa Isailovic³, Maria De Santis⁴, Elena Generali¹, Marco Massarotti⁵, Minoru Satoh⁶ and Carlo Selmi^7,8, ¹Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ²BIOMETRA, University of Milan, Milan, Italy, ³Internal Medicine; Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ⁴Internal Medicine, Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ⁵Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (Milan), Italy, ⁶Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ⁸BIOMETRA Department, University of Milan, Milan, Italy
Background/Purpose: Systemic Sclerosis (SSc), Polymyositis (PM) and Dermatomyositis (DM) are characterized by the presence of serum autoantibodies (autoAbs) which are central in the diagnosis, predicting…
Abstract Number: 2947 • 2015 ACR/ARHP Annual Meeting
Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Seiko Kondo-Ishikawa¹, Takao Fujii², Nozomi Ishigooka¹, Kosaku Murakami¹, Ran Nakashima¹, Yoshitaka Imura¹, Motomu Hashimoto², Naoichiro Yukawa¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Autoantibodies (auto Abs) in cerebrospinal fluid (CSF) and inflammatory mediators (IMs) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). Previous…
Abstract Number: 290 • 2015 ACR/ARHP Annual Meeting
Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients
Yves Allenbach¹, Jeremy Kaeren¹, Nicolas Champtiaux¹, Yoland Schoindre¹, Kuberaka Mariampillai¹, Aude Rigolet¹, Lucile Musset², Jean- Luc Charuel², Anthony Behin³, Bruno Eymard⁴, Pascal Laforet⁵, Tanya Stojkovic⁵, Olivier Boyer⁶, Baptiste Hervier⁷ and Olivier Benveniste¹, ¹Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ²Laboratoire d'immunochimie, Pitié- Salpêtrière, Paris, France, ³Institute of Myology, Pitie-Salpetriere Hospital, Paris, France, ⁴Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁵Department of Neurology, Myology Institute, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁶Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ⁷Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, Paris, France
Background/Purpose: Twenty percent of inflammatory myopathy are associated with a synchronous cancer occurring ±3 years around the diagnosis. Malignancy is a major cause of mortality…
Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting
B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
Shaun Jackson, Nicole Scharping, Holly Jacobs, Tanvi Arkatkar, Socheath Khim and David Rawlings, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].